Clinical Trials
16 trialsNCT07589634 2026-05-15
TRI Pro
Janssen Research & Development, LLC
Phase 2 Not yet recruiting
NCT06948084 2026-05-13
Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse
National Cancer Institute (NCI)
Phase 2 Not yet recruiting
NCT07567014 2026-05-06
Emapalumab Prophylaxis of Bispecific T-Cell Engagers (BiTEs) Associated CRS and ICANS
NYU Langone Health
Phase 2 Not yet recruiting
NCT07009899 2026-05-01
RECLAIM
Medical College of Wisconsin
Phase 2 Not yet recruiting
NCT07485647 2026-03-20
Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing
Vanderbilt-Ingram Cancer Center
Phase 2 Not yet recruiting
NCT07029776 2026-03-03
MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma
University of Arkansas
Phase 2 Not yet recruiting
NCT07409454 2026-02-13
CAREMM-007
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Not yet recruiting
NCT05874193 2026-02-05
COSTA
Duke University
Phase 2 Not yet recruiting
NCT07348393 2026-01-16
Mezi-KD
Assistance Publique - Hôpitaux de Paris
Phase 2 Not yet recruiting
NCT07247097 2025-11-25
ELDORADO
Massachusetts General Hospital
Phase 2 Not yet recruiting
NCT07070934 2025-07-17
ASCTvsCAR-T
Xuzhou Medical University
Phase 2 Not yet recruiting
NCT06963866 2025-05-09
ASCTvsCAR-T
Xuzhou Medical University
Phase 2 Not yet recruiting
NCT06931704 2025-04-23
IFM 2024_06
Nantes University Hospital
Phase 2 Not yet recruiting
NCT06880601 2025-04-03
TALIM
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Not yet recruiting
NCT06744894 2024-12-20
SIL as Maintenance Therapy in Multiple Myeloma
Navy General Hospital, Beijing
Phase 2 Not yet recruiting
NCT05909826 2023-06-18
KMM-KCd
Dong-A University Hospital
Phase 2 Not yet recruiting